255 related articles for article (PubMed ID: 9414391)
1. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
4. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Pratt CB
Semin Oncol; 1996 Jun; 23(3 Suppl 6):84-90. PubMed ID: 8677456
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
[TBL] [Abstract][Full Text] [Related]
11. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
12. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
13. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Dorval T; Soussain C; Beuzeboc P; Garcia-Giralt E; Jouve M; Livartowski A; Mosseri V; Palangié T; Scholl S; Sastre X; Pouillart P
J Infus Chemother; 1996; 6(1):47-9. PubMed ID: 8748008
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
Rassnick KM; Rodriguez CO; Khanna C; Rosenberg MP; Kristal O; Chaffin K; Page RL
Am J Vet Res; 2006 Mar; 67(3):517-23. PubMed ID: 16506920
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
17. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
Meazza C; Casanova M; Luksch R; Podda M; Favini F; Cefalo G; Massimino M; Ferrari A
Pediatr Blood Cancer; 2010 Oct; 55(4):617-20. PubMed ID: 20589638
[TBL] [Abstract][Full Text] [Related]
18. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
19. Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas.
Lopez M; Carpano S; Amodio A; Gionfra T; Della Giulia M; Foggi P; Manfredi C; Del Monte G
Clin Ter; 1998; 149(5):331-3. PubMed ID: 10052244
[TBL] [Abstract][Full Text] [Related]
20. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
